Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04639193 · ClinicalTrials.gov registry record · Phase 2
Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04639193 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 20 participants.
The verdict
NCT04639193, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Obstructive sleep apnea (OSA) is common and associated with many adverse health consequences, but many patients are unable to tolerate standard therapies such as continuous positive airway pressure (CPAP) and thus remain untreated. Single-drug therapies have shown promising results in treating sleep apnea, but on average patients have only experienced partial relief. Multi-drug therapy may offer a more effective treatment approach. The goal of this study is to test the effect of combination therapy with three FDA-approved drugs (Diamox \[acetazolamide\], Lunesta \[eszopiclone\] +/- Effexor \[venlafaxine\]) on OSA severity and physiology.
Interventions
- DRUG Placebo
- DRUG Acetazolamide
- DRUG Eszopiclone
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04639193
The ClinicalTrials.gov registry entry for NCT04639193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04639193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04639193 about?
NCT04639193 is a clinical study titled "Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea". Obstructive sleep apnea (OSA) is common and associated with many adverse health consequences, but many patients are unable to tolerate standard therapies such as continuous positive airway pressure (CPAP) and thus remain untreated. Single-drug therapies have shown promising results in treating sleep...
What is the current status of trial NCT04639193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-12-01. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT04639193?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG), Eszopiclone (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT04639193?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.